The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Liposomal Formulations in Clinical Use: An Updated Review
Open accessAbstract
Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer phospholipid vesicles have witnessed many technical advances in recent years since their first development in 1965. Delivery of therapeutics by liposomes alters their biodistribution profile, which further enhances the therapeutic index of various drugs. Extensive research is being carried out using these nano drug delivery systems in diverse areas including the delivery of anti-cancer, anti-fungal, anti-inflammatory drugs and therapeutic genes. The significant contribution of liposomes as drug delivery systems in the healthcare sector is known by many clinical products, e.g., Doxil®, Ambisome®, DepoDur™, etc. This review provides a detailed update on liposomal technologies e.g., DepoFoam™ Technology, Stealth technology, etc., the formulation aspects of clinically used products and ongoing clinical trials on liposomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664 · cited 1×
“Alec Bangham, in 1961 [1], first described liposomes.”
Background(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
Torchilin, V. P. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4333 · Cited by 1,663
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Gabizón, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., & Barenholz, Y. (1994) · PubMed · Cited by 1,382
Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.015 · Cited by 1,288
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222 · cited 1×
“5 months for those who consumed either fluorouracil or leucovorin [45].”
BackgroundYeh, M.-K., Chang, H.-I., & Cheng, M.-Y. (2011) · International Journal of Nanomedicine · doi:10.2147/ijn.s26766 · Cited by 801
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Liposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659
Zylberberg, C., & Matosevic, S. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1177136 · Cited by 627
Glantz, M., Jaeckle, K. A., Chamberlain, M. C., Phuphanich, S., Recht, L. D., Swinnen, L. J., Maria, B., LaFollette, S., Schumann, G. B., Cole, B. F., et al. (1999) · PubMed · Cited by 529
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Tumour-inhibiting platinum complexes—state of the art and future perspectives
Jakupec, M. A., Galanski, M. S., & Keppler, B. K. (2003) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/s10254-002-0001-x · Cited by 434
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Zuckerman, J. E., & Davis, M. E. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4685 · Cited by 424
Drummond, D. C., Noble, C. O., Guo, Z., Hong, K., Park, J. W., & Kirpotin, D. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4007 · Cited by 380
Liposomes : a practical approach
Torchilin, V. P., & Weissig, V. (2003) · Medical Entomology and Zoology · Cited by 341
Zhang, J. A., Anyarambhatla, G., Ma, L., Ugwu, S., Xuan, T., Sardone, T., & Ahmad, I. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.06.009 · Cited by 334
Liposomes: A Practical Approach
(2003) · doi:10.1093/oso/9780199636556.001.0001 · Cited by 284
Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin
Boulikas, T. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903114168 · Cited by 276
Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, B., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0082331 · Cited by 273
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
Egusquiaguirre, S. P., Igartua, M., Hernández, R. M., & Pedraz, J. L. (2012) · Clinical and Translational Oncology · doi:10.1007/s12094-012-0766-6 · Cited by 268
Advances in Platinum Chemotherapeutics
Harper, B. W., Krause‐Heuer, A. M., Grant, M. P., Manohar, M., Garbutcheon‐Singh, K. B., & Aldrich‐Wright, J. R. (2010) · Chemistry – A European Journal · doi:10.1002/chem.201000148 · Cited by 267
Gelation of liposome interior A novel method for drug encapsulation
Lasic, D. D., Frederik, P. M., Stuart, M. C. A., Barenholz, Y., & McIntosh, T. J. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80947-f · Cited by 261
Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S. (2009) · The Breast · doi:10.1016/j.breast.2009.05.004 · Cited by 257
Liposome circulation time and tumor targeting: implications for cancer chemotherapy
Gabizon, A. A. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00030-b · Cited by 255
Adler-moore, J. P., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 251
Liposomal drug formulations in cancer therapy: 15 years along the road
Slingerland, M., Guchelaar, H.-J., & Gelderblom, H. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.09.015 · Cited by 250
Advantages of liposomal delivery systems for anthracyclines
Allen, T. M., & Martin, F. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.001 · Cited by 248
Webb, M., Harasym, T., Masin, D., Bally, M., & Mayer, L. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.430 · Cited by 243
Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.
Gill, P. S., Espina, B. M., Muggia, F., Cabriales, S., Tulpule, A., Esplin, J. A., Liebman, H. A., Forssen, E., Ross, M. E., & Levine, A. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.4.996 · Cited by 242
New therapeutic strategies for the treatment of acute lymphoblastic leukaemia
Pui, C.-H., & Jeha, S. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2240 · Cited by 236
Introduction and overview of peptide and protein pegylation
(2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00020-0 · Cited by 235
AmBisome (Liposomal Amphotericin B): A Comparative Review
Boswell, G. W., Buell, D., & Bekersky, I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04464.x · Cited by 227
Unusual lipid structures selectively reduce the toxicity of amphotericin B.
Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T., Gruner, S. M., Shyamsunder, E., & Tate, M. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6122 · Cited by 223
Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection
Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., Lymp, J., Minic, P., Quittner, A. L., Rubenstein, R. C., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202230 · Cited by 222
Development and characterization of a novel liposome-based formulation of SN-38
Zhang, J. A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., & Ahmad, I. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.10.015 · Cited by 220
A review of the current status of siRNA nanomedicines in the treatment of cancer
Resnier, P., Montier, T., Mathieu, V., Benoit, J.-P., & Passirani, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.060 · Cited by 210
Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery.
Lasic, D. D., Čeh, B., Stuart, M. C. A., Guo, L., Frederik, P. M., & Barenholz, Y. (1995) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(95)00159-z · Cited by 209
Immunogenicity of new virosome influenza vaccine in elderly people
Glück, R., Mischler, R., Finkel, B., Que, J. U., Cryz, S. J., & Scarpa, B. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92758-8 · Cited by 199
Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy
Lee, J.-M., Yoon, T.-J., & Cho, Y.-S. (2013) · BioMed Research International · doi:10.1155/2013/782041 · Cited by 190
Walsh, T. J., Yeldandi, V., McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., Seibel, N. I., Whitcomb, P. O., Jarosinski, P., Boswell, G., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2391 · Cited by 189
Richter, A. M., Waterfield, E., Jain, A. K., Canaan, A. J., Allison, B. A., & Levy, J. G. (1993) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1993.tb02962.x · Cited by 182
Angst, M. S., & Drover, D. R. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645120-00002 · Cited by 173
Johnston, M., Semple, S. C., Klimuk, S. K., Edwards, K., Eisenhardt, M. L., Leng, E. C., Karlsson, G., Yanko, D., & Cullis, P. R. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.01.009 · Cited by 172
Wolf, P., Müllegger, R. R., Peter Soyer, H., Hofer, A., Smolle, J., Horn, M., Cerroni, L., Hofmann-Wellenhof, R., Kerl, H., Maier, H., et al. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00839.x · Cited by 170
Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.
White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J., Cantor, A. B., Gurwith, M., Mond, C. D., Mamelok, R. D., & Bowden, R. A. (1997) · PubMed · Cited by 166
Zamboni, W. C., Gervais, A. C., Egorin, M. J., Schellens, J. H. M., Zuhowski, E. G., Pluim, D., Joseph, E., Hamburger, D. R., Working, P. K., Colbern, G., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0719-4 · Cited by 165
Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).
Working, P. K., & Dayan, A. D. (1996) · PubMed · Cited by 156
Strategies for Cancer Vaccine Development
Vergati, M., Intrivici, C., Huen, N., Schlom, J., & Tsang, K. Y. (2010) · BioMed Research International · doi:10.1155/2010/596432 · Cited by 155
Extended CSF cytarabine exposure following intrathecal administration of DTC 101.
Kim, S., Chatelut, É., Kim, J. C., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.11.2186 · Cited by 153
Virosome-mediated delivery of protein antigens to dendritic cells
Bungener, L. B., Serre, K., Bijl, L., Leserman, L., Wilschut, J., Daemen, T., & Machy, P. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00103-2 · Cited by 147
Rodriguez, M. A., Pytlík, R., Kozák, T., Chhanabhai, M., Gascoyne, R. D., Lu, B., Deitcher, S. R., & Winter, J. N. (2009) · Cancer · doi:10.1002/cncr.24359 · Cited by 145
Immunogenicity and protectivity of a new liposomal hepatitis A vaccine
Ambrosch, F. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00015-7 · Cited by 140
Long Circulating Liposomes: Old Drugs, New Therapeutics
Woodle, M. C., & Storm, G. (1998) · Springer eBooks · doi:10.1007/978-3-662-22115-0 · Cited by 137
Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).
Cowens, J. W., Creaven, P. J., Greco, W. R., Brenner, D. E., Tung, Y., Ostro, M. J., Pilkiewicz, F. G., Ginsberg, R. S., & Petrelli, N. J. (1993) · PubMed · Cited by 136
Liposomal daunorubicin as treatment for Kaposi’s sarcoma
Dittmer, D. P., & Petre, C. E. (2007) · PubMed Central · doi:10.17615/wyf0-9n94 · Cited by 130
Krishna, R., Webb, M. S., St.-Onge, G., & Mayer, L. D. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29494-5 · Cited by 129
Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study
Stathopoulos, G. P., Boulikas, T., Vougiouka, M., Deliconstantinos, G., Rigatos, S., Darli, E., Viliotou, V., & Stathopoulos, J. (2005) · Oncology Reports · doi:10.3892/or.13.4.589 · Cited by 128
Vail, D. M., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R., Helfand, S. C., Kisseberth, W. C., London, C. A., Obradovich, J. E., Madewell, B. R., & Rodriguez, C. O. (1995) · PubMed · Cited by 128
Systemic Lipoplatin infusion results in preferential tumor uptake in human studies.
Boulikas, T., Stathopoulos, G. P., Volakakis, N., & Vougiouka, M. (2005) · PubMed · Cited by 126
Birngruber, T., Raml, R., Gladdines, W., Gatschelhofer, C., Gander, E., Ghosh, A., Altendorfer‐Kroath, T., Gaillard, P. J., Pieber, T. R., & Sinner, F. M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23994 · Cited by 125
Janoff, A. S., Perkins, W. R., Saletan, S., & Swenson, C. E. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150730 · Cited by 122
Bowden, R. A., Cays, M., Gooley, T. A., Mamelok, R. D., & van Burik, J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.5.1208 · Cited by 117
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
Alphandéry, E., Grand-Dewyse, P., Lefèvre, R., Mandawala, C., & Durand‐Dubief, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1086647 · Cited by 115
Characterization of Nebulized Liposomal Amikacin (Arikace ™ ) as a Function of Droplet Size
Li, Z., Zhang, Y., Wurtz, W., Lee, J. K., Malinin, V., Durwas-Krishnan, S., Meers, P. R., & Perkins, W. R. (2008) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2008.0686 · Cited by 112
Fielding, R. M., Singer, A. W., Wang, L. H., Babbar, S., & Guo, L. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.299 · Cited by 110
Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs
Guo, L. S. S., Fielding, R. M., Lasiç, D. D., Hamilton, R. L., & Mufson, D. (1991) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(91)90249-n · Cited by 110
Conne, P., Gauthey, L., Vernet, P., Althaus, B., Que, J. U., Finkel, B., Glück, R., & Cryz, S. J. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00087-x · Cited by 106
Clinical Pharmacology of Encapsulated Sustained-Release Cytarabine
Murry, D. J., & Blaney, S. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19347 · Cited by 99
Mylonakis, N., Athanasiou, A. E., Ziras, N., Angel, J., Rapti, A., Lampaki, S., Politis, N., Karanikas, C. A., & Kosmas, C. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.017 · Cited by 98
Phototriggerable Liposomes: Current Research and Future Perspectives
Puri, A. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics6010001 · Cited by 94
Adedoyin, A. B., Bernardo, J. F., Swenson, C. E., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2201 · Cited by 92
Zamboni, W. C., Strychor, S., Joseph, E., Walsh, D. R., Zamboni, B. A., Parise, R. A., Tonda, M. E., Yu, N. Y., Engbers, C. M., & Eiseman, J. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1035 · Cited by 89
Slingerland, M., Guchelaar, H., Rosing, H., Scheulen, M. E., van Warmerdam, L. J. C., Beijnen, J. H., & Gelderblom, H. A. J. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.10.009 · Cited by 89
Pharmacokinetics of Intralumbar DTC-101 for the Treatment of Leptomeningeal Metastases
Chamberlain, M. C., Kormanik, P. A., Howell, S. B., & Kim, S. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540330094020 · Cited by 86
Eichhorn, M., Ischenko, I., Luedemann, S., Strieth, S., Papyan, A., Werner, A., Bohnenkamp, H. R., Guenzi, E., Preißler, G., Michaelis, U., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24846 · Cited by 85
Bradbury, P. A., & Shepherd, F. A. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174e9a7 · Cited by 83
Stathopoulos, G., Boulikas, T., Vougiouka, M., Rigatos, S., & Stathopoulos, J. (2006) · Oncology Reports · doi:10.3892/or.15.5.1201 · Cited by 82
LISTER, J. W. (1996) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1996.tb01348.x · Cited by 81
Douer, D., Estey, E. H., Santillana, S., Bennett, J. M., Lopez-Bernstein, G., Boehm, K. A., & Williams, T. (2001) · Blood · doi:10.1182/blood.v97.1.73 · Cited by 81
Sanders, S. W., Buchi, K. N., Goddard, M. S., Lang, J. K., & Tolman, K. G. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.6.1029 · Cited by 80
Tissue Distribution of Amphotericin B Lipid Complex in Laboratory Animals
Olsen, S., Swerdel, M. R., Blue, B., Clark, J. M., & BONNER, D. P. (1991) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1991.tb03189.x · Cited by 79
Perez, O., Herzog, C., Zellmeyer, M., Loáisiga, A., Frösner, G., & Egger, M. (2003) · The Journal of Infectious Diseases · doi:10.1086/377309 · Cited by 76
Long‐term immunogenicity of an inactivated virosome hepatitis A vaccine
BOVIER, P. A., Bock, J., Loutan, L., Farinelli, T., Glueck, R., & Herzog, C. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10244 · Cited by 75
Harrington, K. J., Rowlinson‐Busza, G., Syrigos, K. N., Vile, R. G., Uster, P. S., Peters, A. M., & Stewart, J. S. W. (2000) · PubMed · Cited by 75
T4 endonuclease V: review and application to dermatology
Cafardi, J. A., & Elmets, C. A. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.829 · Cited by 72
New technology platforms in the development of vaccines for the future
Glück, R., & Metcalfe, I. C. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00513-3 · Cited by 72
Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas
Gupta, V. K., Su, Y. S., Samuelson, C. G., Liebes, L., Chamberlain, M. C., Hofman, F. M., Schönthal, A. H., & Chen, T. C. (2007) · Journal of neurosurgery · doi:10.3171/jns.2007.106.3.455 · Cited by 72
Kanter, P. M., Bullard, G. A., Pilkiewicz, F. G., Mayer, L. D., Cullis, P. R., & Pavelic, Z. P. (1993) · PubMed · Cited by 68
Cardiac safety of liposomal anthracyclines
Batist, G. (2007) · Cardiovascular Toxicology · doi:10.1007/s12012-007-0014-4 · Cited by 62
Harasym, T. O., Cullis, P. R., & Bally, M. B. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050662 · Cited by 59
Wang, L. H., Fielding, R. M., Smith, P. C., & Guo, L. S. S. (1995) · Pharmaceutical Research · doi:10.1023/a:1016243313027 · Cited by 55
Victories and deceptions in tumor immunology
Kroemer, G., Zitvogel, L., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23687 · Cited by 54
Extended‐Release Epidural Morphine (DepoDur™): An Old Drug with a New Profile
Alam, M., & Hartrick, C. T. (2005) · Pain Practice · doi:10.1111/j.1533-2500.2005.00048.x · Cited by 52
Chen, J., He, C., Lin, A.-H., Gu, W., Chen, Z., Li, W., & Cai, B. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.09.009 · Cited by 50
Enhanced brain drug delivery: safely crossing the blood–brain barrier
Gaillard, P. J., Visser, C. C., Appeldoorn, C. C. M., & Rip, J. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.12.002 · Cited by 50
Wetzler, M., Thomas, D. A., Wang, E. S., Shepard, R. C., Ford, L. A., Heffner, T. L., Parekh, S. S., Andreeff, M., O'Brien, S. M., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.03.015 · Cited by 45
Clarke, P. D., Adams, P., Ibáñez, R., & Herzog, C. (2006) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2006.01.001 · Cited by 43
Arlinghaus, R. B., Lopez‐Berestein, G., Belmont, J. W., Rosenblum, M. G., Sun, T., Stephens, C. L., Monaco, G., Gutiérrez-Puente, Y., & Tari, A. M. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.5.1243 · Cited by 38
Repairing DNA damage in xeroderma pigmentosum: T4N5 lotion and gene therapy.
Zahid, S., & Brownell, I. (2008) · PubMed · Cited by 38
Enhanced Unscheduled DNA Synthesis in UV-Irradiated Human Skin Explants Treated with T4N5 Liposomes
Yarosh, D. B., Kibitel, J. T., Green, L. A., & Spinowitz, A. L. (1991) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12479314 · Cited by 33
Fumagalli, L. A. M., Zucchetti, M., Parisi, I., Viganò, M. G., Zecca, B., Careddu, A., D’Incalci, M., & Lazzarin, A. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051025 · Cited by 31
Madden, T. D., Janoff, A. S., & Cullis, P. R. (1990) · Chemistry and Physics of Lipids · doi:10.1016/0009-3084(90)90114-7 · Cited by 30
Liposomal delivery of nucleic acid-based anticancer therapeutics: BP-100-1.01
Ashizawa, A. T., & Cortes, J. E. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.996545 · Cited by 28
Yu, N. Y., Conway, C., Pena, R. L., & Chen, J. Y. (2007) · PubMed · Cited by 24
Schuch, G. (2005) · PubMed · Cited by 19
Nanotechnology for enhanced bioactivity of bioactive phytomolecules
Singh, R., Kumari, P., & Kumar, S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804304-2.00011-1 · Cited by 19
Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application
Egusquiaguirre, S. P., Pedraz, J. L., Hernández, R. M., & Igartua, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-47347-7.00029-x · Cited by 14
Cited by
Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10020057 · Cited by 4,832
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561
Design of liposomes as drug delivery system for therapeutic applications
Guimarães, D., Cavaco-Paulo, A., & Nogueira, E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120571 · Cited by 1,196
Metadata
- Authors
- Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2017-03-27
- Volume
- 9
- Issue
- 2
- Pages
- 12
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W2599276599
- Cited by
- 2,156
- References
- 115
- FWCI
- 59.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.